Ractigen Therapeutics, founded in 2017 by RNAa pioneers Dr. Long-Cheng Li, Dr. Robert Place and Dr. Moorim Kang, develops therapies that use small activating RNAs (saRNA) to up‑regulate targeted endogenous genes. The company has built an SCAD delivery system designed to improve biodistribution in extrahepatic tissues and claims a pipeline of first‑in‑class candidate medicines for unmet genetic disorders. Ractigen is a late‑stage preclinical company focused on advancing multiple programs toward clinical development. It is scaling oligonucleotide manufacturing capabilities to support progression of programs. The company closed an additional Series A+ financing to fund these development and manufacturing plans. All information here is sourced from the provided article.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022